Vertex Pharmaceuticals IncorporNasdaq: VRTX
Health Care · Biotechnology
$451.94
-1.54%
Vol: 1.5M
Research Digest
Friday, June 19, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 18Vertex receives FDA BLA acceptance for povetacicept in IgA nephropathy and presents positive ALYFTREK pediatric Phase 3 data, broadening its pipeline beyond cystic fibrosis.Positive▶
The U.S. FDA accepted Vertex's Biologics License Application for povetacicept for accelerated approval in IgA nephropathy on June 1, 2026, marking a meaningful regulatory milestone in Vertex's nephrology expansion. On June 5 and 12, Vertex presented Phase 3 data showing ALYFTREK improved CF transmembrane conductance regulator function in children ages 2–5 already on TRIKAFTA, and TRIKAFTA showed clinical benefit in children ages 1 to under 2, supporting global regulatory submissions for these younger populations. At the European Hematology Association Congress on June 11, Vertex presented CASGEVY data in children ages 5–11, expanding the gene-editing therapy label push. VRTX traded near $459 on June 17, roughly flat year-to-date. Insider sales by CMO Carmen Bozic (4,062 shares on June 15) and CLO Joy Liu (828 shares on June 1) were pre-planned 10b5-1 transactions. Risk is pipeline execution beyond CF and the competitive nephrology landscape.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15Vertex shares traded in a tight $440-$448 range on June 14 as the company showcased fresh Casgevy data at EHA and pediatric ALYFTREK cystic fibrosis results, reinforcing pipeline momentum.Positive▶
Vertex Pharmaceuticals presented new clinical data at the European Hematology Association (EHA) congress for its gene therapy Casgevy in sickle cell disease, alongside data on ALYFTREK in children with cystic fibrosis. The stock traded between $440.02 and $447.70 on June 14, closing near $444.91, trading below the consensus price target of roughly $494. The updates follow recent regulatory wins including FDA acceptance of a BLA for povetacicept in IgA nephropathy and a CF triple-combination label extension reaching ~95% of US CF patients. Insiders have been net buyers over the past three months (~$1.95M purchased), a constructive signal. Consensus rating is Moderate Buy. The bear case: Vertex remains heavily reliant on its CF franchise, and newer pipeline assets like povetacicept and the acute-pain drug must prove commercial traction to justify the valuation, while Wall Street Zen recently downgraded the stock to Hold.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Vertex secures national CASGEVY reimbursement deal with Germany's GKV-Spitzenverband, expanding gene-therapy accessPositive▶
Vertex Pharmaceuticals reached a national reimbursement agreement with Germany's GKV-Spitzenverband (the main association of statutory health insurers) for one-time CRISPR/Cas9 therapy CASGEVY, giving the company clearer pricing visibility for eligible sickle cell disease and beta thalassemia patients in a major European market. The deal supports Vertex's reaffirmed 2026 revenue guidance of $12.95B-$13.10B, which includes at least $500M from non-CF products. The annual shareholder meeting on May 13 approved the 2025 NEO compensation package and a written-consent proposal. CMO Carmen Bozic sold 6,988 shares on May 12.
May 20Multiple analysts raised Vertex price targets in mid-May after the company signed a German CASGEVY reimbursement deal and filed a $2.87B ESOP shelf registration.Positive▶
In early May 2026, Vertex Pharmaceuticals signed a reimbursement agreement with Germany's GKV-Spitzenverband for its one-time CRISPR/Cas9 sickle-cell therapy CASGEVY, expanding patient access in Europe. The company also filed a new $2.87B shelf registration for 6.4M shares tied to its employee stock ownership plan. On May 13, 2026, shareholders re-elected ten directors, ratified Ernst & Young as 2026 auditor, approved executive pay, and backed the 2026 Stock and Option Plan. Multiple analysts raised price targets: Morgan Stanley to $616 (Overweight), Barclays to $615 (Overweight), and RBC Capital's Brian Abrahams to $543 (Outperform). Pipeline catalysts include povetacicept Phase 3 success in IgA nephropathy and a mid-stage Myasthenia Gravis trial. The stock closed at $437.42 on May 19, 2026.
May 19Vertex files updated Phase 2 povetacicept myasthenia gravis trial on May 15, expanding pipeline beyond cystic fibrosis into autoimmune carePositive▶
Vertex Pharmaceuticals filed an updated regulatory listing for its Phase 2 study of povetacicept in generalized myasthenia gravis on May 15, 2026, signaling expansion of the non-CF portfolio into autoimmune disease. The move follows a strong Q1 with $2.99B revenue, EPS of $4.47, reaffirmed full-year 2026 guidance of $12.95B-$13.10B, and management's expectation of at least $500M in non-CF revenue this year, with CASGEVY and JOURNAVX accounting for over 25% of quarterly growth. Vertex also secured a CASGEVY reimbursement agreement in Germany for sickle-cell disease and TDT, and filed a $2.87B ESOP-linked shelf registration for 6.4M shares. The bear case is dilution and pipeline-execution risk on autoimmune entry, with the stock trading 16% below 52-week highs. Morgan Stanley raised its price target to $616 from $612, maintaining Overweight.
May 18Vertex Pharmaceuticals shareholders approve 2026 stock plan on May 13 amid CASGEVY German reimbursement deal and reaffirmed $12.95B-$13.10B revenue guidancePositive▶
Vertex shareholders approved the 2026 stock plan and ratified Ernst & Young as auditor at the May 13, 2026 annual meeting. The company secured a national reimbursement agreement with Germany's GKV-Spitzenverband for CASGEVY, marking Germany's first long-term access deal for a gene-edited therapy of this kind for sickle cell disease and beta thalassemia patients. Vertex reaffirmed full-year 2026 revenue guidance of $12.95B-$13.10B after Q1 revenue of $2,986.9M and net income of $1,031.4M. The company filed a new $2.87 billion shelf registration for 6.4 million shares tied to its employee stock ownership plan. Bear case: shares fell roughly 3.7% intraday on May 17 to $437.87 and CMO Carmen Bozic sold 6,988 shares on May 12; the stock remains pressured by gene-therapy commercialization uncertainty and concentration risk in cystic fibrosis franchise.
May 15Vertex secured a German CASGEVY reimbursement deal with GKV-Spitzenverband and shareholders approved its 2026 stock plan at the May 13 annual meeting.Positive▶
Vertex Pharmaceuticals secured a reimbursement agreement in Germany for its CASGEVY gene therapy for sickle cell disease and beta thalassemia with GKV-Spitzenverband, the main association of statutory health insurers, providing clearer pricing and access visibility in a key European market. Shareholders approved the 2026 stock plan at the May 13 annual meeting. The company reaffirmed FY26 revenue guidance of $12.95B-$13.10B after Q1 revenue of $2.99B. Vertex will participate in RBC's Healthcare Conference (May 19) and Bernstein's Strategic Decisions Conference (May 29). Stock trades around $425, down ~6% YTD, with average analyst target of $541.
May 14Vertex secures Germany CASGEVY reimbursement deal and holds annual meeting amid Q1 missMixed▶
Vertex Pharmaceuticals held its annual shareholder meeting on May 13, 2026, with directors re-elected and the 2026 Stock and Option Plan approved by a wide margin. Earlier, on May 6, the company secured a reimbursement agreement in Germany for CASGEVY gene therapy for sickle cell disease and transfusion-dependent beta thalassemia, marking Germany's first long-term access deal for a gene-edited therapy. Q1 2026 revenue of $2.99 billion and net income of $1.03 billion came in below consensus of $3.09 billion, although full-year revenue guidance of $12.95-$13.10 billion was reaffirmed. RBC Capital raised its price target to $543 from $541 on May 5 while keeping a Buy rating. The bear case focuses on CF franchise concentration and uncertainty on povitacicept in IgA nephropathy.
May 13Vertex secures CASGEVY reimbursement deal in Germany, broadening commercial access beyond cystic fibrosis franchise.Positive▶
Vertex announced a CASGEVY reimbursement agreement with GKV-Spitzenverband, Germany's main statutory health insurer, for sickle cell disease and transfusion-dependent beta thalassemia. This provides clearer access and pricing visibility in a key European market and supports management's guidance for at least $500M in non-CF revenue in 2026 from CASGEVY and JOURNAVX. Q1 2026 revenue was $2.99B (+8% YoY), and positive Phase 3 interim data from the RAINIER study in IgA nephropathy strengthens the late-stage pipeline. Risk: CASGEVY commercial ramp has been slow due to complex apheresis logistics, and the stock is down 6% YTD on competition concerns. Average analyst PT is $541 (~24% upside).
May 12Vertex secures CASGEVY gene therapy reimbursement deal in Germany, expanding access for sickle cell and beta thalassemia patientsMixed▶
On May 8, 2026, Vertex Pharmaceuticals announced a reimbursement agreement with Germany's GKV-Spitzenverband for its CRISPR/Cas9 gene therapy CASGEVY, ensuring sustainable access for patients aged 12+ with severe sickle cell disease or transfusion-dependent beta thalassemia. The deal expands the commercial footprint of the one-time gene therapy. Q1 2026 revenue was $2.99B (+8% YoY) with net income $1.03B and diluted EPS $4.02 (+61% YoY); however revenue and EPS came in below consensus. Vertex reaffirmed full-year revenue guidance of $12.95B-$13.10B and expects $500M+ in non-CF revenue this year, up from $175M last year. CFO Charlie Wagner will speak at RBC Healthcare on May 19; CEO Reshma Kewalramani at Bernstein SDC on May 29. Stock around $425, down ~6% YTD.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABBVABBVIE | $216.79 | -2.01% | +2.0% | 13.3x | 0.31 | $382.5B |
| AMGNAMGEN | $337.43 | -1.24% | +1.8% | 14.4x | 0.42 | $182.2B |
| GILDGILEAD | $123.76 | -1.35% | -5.3% | 12.8x | 0.33 | $153.7B |
| VRTXVERTEX | $451.94 | -1.54% | +4.9% | 21.0x | 0.31 | $114.6B |
| REGNREGENERON | $609.97 | +0.34% | -6.1% | 11.3x | 0.24 | $63.9B |
| BIIBBIOGEN | $196.51 | -1.09% | +4.7% | 11.8x | 0.18 | $29.0B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.